Doitsh, G. & Greene, W.C. Investigation of how CD4 T cells are lost during HIV infection. Cell Host Microbe 19, 280-291 (2016).
Churchill, M.J., Deeks, S.G., Margolis, D.M., Siliciano, R.F. & Swanstrom, R. HIV reservoirs: what, where and how to target them. Nat. Rev. Microbiol, 14, 55-60 (2016).
Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. nature 543, 559-563 (2017).
Gautam, R. et al. A single injection of crystallizable fragment-domain-modified antibodies triggers permanent protection against SHIV infection. Nat. med, 24, 610-616 (2018).
Schoofs, T. et al. HIV-1 therapy with the monoclonal antibody 3BNC117 triggers host immune responses to HIV-1. science 352, 997-1001 (2016).
Caskey, M. et al. Viremia was suppressed in HIV-1-infected humans by largely neutralizing the antibody 3BNC117. nature 522, 487-491 (2015).
Lynch, R.M. et al. Virological effects of extensive neutralization of antibody VRC01 administration during chronic HIV-1 infection. Sci. Translation Med, 7, 319ra206 (2015).
Caskey, M. et al. The antibody 10-1074 suppresses viremia in HIV-1 infected individuals. Nat. med, 23, 185-191 (2017).
Scheid, J.F. et al. The HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. nature 535, 556-560 (2016).
Li, J.Z. et al. The size of the expressed HIV reservoir predicts the timing of the viral rebound after treatment interruption. AIDS 30, 343-353 (2016).
Bar, K.J. et al. Effect of the HIV antibody VRC01 on the viral rebound after treatment interruption. N. Engl. J. Med, 375, 2037-2050 (2016).
Shingai, M. et al. Passive transmission of modest titers of potent and largely neutralizing monoclonal anti-HIV antibodies block SHIV infection in macaques. J. Exp. Med, 211, 2061-2074 (2014).
Gautam, R. et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. nature 533, 105-109 (2016).
Klein, F. et al. HIV therapy by a combination of largely neutralizing antibodies in humanized mice. nature 492, 118-122 (2012).
Horwitz, J.A. et al. HIV-1 suppression and long-term control by combining single largely neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl Acad. Sci. USA 110, 16538-16543 (2013).
Shingai, M. et al. Antibody-mediated immunotherapy of chronically SHIV infected macaques suppresses viremia. nature 503, 277-280 (2013).
Trkola, A. et al. Delay in the recurrence of HIV-1 after cessation of antiretroviral therapy by passive transfer of neutralizing human antibodies. Nat. med, 11, 615-622 (2005).
Mehandru, S. et al. Concomitant passive immunotherapy in type 1 infected humans who are infected with the immunodeficiency virus and who have been treated during an acute and an early infection with antiviral therapy. J. Virol, 81, 11016-11031 (2007).
Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for the standardized evaluation of neutralizing antibodies to HIV-1. J. Immunol. methods 409, 131-146 (2014).
Cohen, Y. Z. et al. Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J. Exp. Med, 215, https://doi.org/10.1084/jem.20180936 (2018).
Robertson, D.L., Sharp, P.M., McCutchan, F.E. & Hahn, B.H. Recombination in HIV-1. nature 374, 124-126 (1995).
Rothenberger, M.K. et al. A large number of Rebounding / Founder HIV variants are caused by multifocal infection in lymphoid tissues after treatment interruption. Proc. Natl Acad. Sci. USA 112, E1126-E1134 (2015).
Kearney, M.F. et al. Absence of detectable HIV-1 molecular evolution during antiretroviral suppressive therapy. PLoS-Pathog, 10, e1004010 (2014).
Lorenzi, J.C. et al. Paired quantitative and qualitative assessment of replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. Proc. Natl Acad. Sci. USA 113, E7908-E7916 (2016).
Wang, Z. et al. Extended cellular clones carrying replication-competent HIV-1 persist, grow, and lose. Proc. Natl Acad. Sci. USA 115, E2575-E2584 (2018).
Hosmane, N.N. et al. Proliferation of latently infected CD4+ T-cells carrying replication-competent HIV-1: potential role in latent reservoir dynamics. J. Exp. Med, 214, 959-972 (2017).
Crooks, A.M. et al. Precise Quantification of the HIV-1 Latent Reservoir: Implications for Eradication Strategies. J. Infect. Dis, 212, 1361-1365 (2015).
Poignard, P. et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. immunity 10, 431-438 (1999).
Scheid, J.F. et al. A method for identifying HIV gp140 binding of memory B cells in human blood. J. Immunol. methods 343, 65-67 (2009).
Escolano, A., Dosenovic, P. & Nussenzweig, M. C. Advances Towards Active or Passive HIV-1 Inoculation. J. Exp. Med, 214, 3-16 (2017).
Kwong, P.D. & Mascola, J.R. HIV-1 vaccines based on antibody identification, B cell ontogenesis and epitope structure. immunity 48, 855-871 (2018).
Lu, C.L. et al. Increased clearance of HIV-1-infected cells by largely neutralizing antibodies to HIV-1 in vivo. science 352, 1001-1004 (2016).
Walker, B.D. & Yu. X. G. Unravel the mechanisms of permanent control of HIV-1. Nat. Rev. Immunol, 13, 487-498 (2013).
Colby, D.J. et al. Rapid HIV-RNA rebound after antiretroviral treatment interruption in individuals who have been permanently suppressed in Fiebig I acute HIV infection. Nat. med, 24, 923-926 (2018).
Sáez-Cirion, A. et al. Follow-up treatment HIV-1 controller with a long-term virologic remission after interruption of early-onset antiretroviral therapy ANRS VISCONTI study. PLoS-Pathog, 9, e1003211 (2013).
Sneller, M.C. et al. A randomized, controlled trial on the safety / efficacy of a therapeutic vaccine in HIV-infected individuals who initiated antiretroviral therapy early in the infection. Sci. Translation Med, 9, eaan8848 (2017).
Fidler, S. et al. Virological blips and predictors of viral control after treatment after termination of ART began with primary HIV infection. J. Acquir. Immunodeficiency. Syndr, 74, 126-133 (2017).
Martin, G.E. et al. Post-treatment or treated controller? Viral remission in treated and untreated primary HIV infection. AIDS 31, 477-484 (2017).
Cohn, L.B. et al. Clonal CD4+ T cells in the latent HIV-1 reservoir show a pronounced gene profile upon reactivation. Nat. med, 24, 604-609 (2018).
Maldarelli, F. et al. Specific HIV integration sites are associated with clonal expansion and persistence of infected cells. science 345, 179-183 (2014).
Wagner, T.A. et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. science 345, 570-573 (2014).
Cohn, L.B. et al. HIV-1 integration landscape with latent and active infection. cell 160, 420-432 (2015).
Halper-Stromberg, A. et al. Highly neutralizing antibodies and viral inducers reduce the rebound of HIV-1 latent reservoirs in humanized mice. cell 158, 989-999 (2014).
Ko, S.Y. et al. Improved neonatal Fc receptor function enhances protection against primate SHIV infection. nature 514, 642-645 (2014).
Gaudinski, M.R. et al. Safety and pharmacokinetics of the Fc-modified human monoclonal HIV-1 antibody VRC01LS: an open-label, phase 1 clinical trial in healthy adults. PLoS Med, 15, e1002493 (2018).
Salazar-Gonzalez, J.F. et al. Deciphering the transmission of human immunodeficiency virus type 1 and diversification of the early envelope by single genome amplification and sequencing. J. Virol, 82, 3952-3970 (2008).
Kirchherr, J.L. et al. High throughput functional analysis of HIV-1 env Genes without cloning. J. Virol. methods 143, 104-111 (2007).
Larkin, M.A. et al. Clustal W and Clustal X Version 2.0. Bioinformatics 23, 2947-2948 (2007).
Guindon, S. et al. New Algorithms and Methods for Estimating Phylogenies with Maximum Likelihood: Assessing the Performance of PhyML 3.0. Syst. Biol, 59, 307-321 (2010).
Stamatakis, A. RAxML Version 8: A tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30, 1312-1313 (2014).